Abstract 124: IRG1-Itaconate Axis Protects From Cholesterol-Induced Inflammation And Atherosclerosis
Fazli K Bozal,Yannick Cyr,Jose Gabriel Barcia Duran,Alexandra AC Newman,Letizia Amadori,Panagiotis Smyrnis,Morgane Gourvest,Dayasagar Das,Michael Gildea,Ravneet Kaur,Tracy Zhang,Kristin M Wang,Richard Von Itter,Ann Marie Schmidt,Edward A Fisher,Coen van Solingen,Chiara Giannarelli,Kathryn J Moore
DOI: https://doi.org/10.1161/atvb.44.suppl_1.124
2024-05-01
Abstract:Atherosclerosis, the major underlying cause of cardiovascular disease (CVD) mortality, is fueled by a failure to resolve lipid-driven inflammation within the vessel wall. Understanding the immunometabolic mechanisms underpinning sustained inflammation within this microenvironment is needed for the development of novel targeted therapies. Immune responsive gene 1 (IRG) is an enzyme that diverts the TCA cycle intermediate, cis-aconitate, to produce itaconate, a metabolite with anti-microbial and anti-inflammatory functions. We used a translational approach to investigate the therapeutic potential of the Irg1-itaconate axis for human atherosclerosis. Using single cell RNA-sequencing, we found that IRG1 is upregulated in human coronary atherosclerotic lesions compared to patient-matched healthy vasculature, and is primarily expressed by plaque monocytes and macrophages. In mouse models of atherosclerosis, Irg1 was expressed by plaque monocytes, macrophage and neutrophils, but declined with disease progression. Global or hematopoietic Irg1 -deficiency increased atherosclerosis burden, plaque lipid content, and expression of interleukin (IL)-1b. Mechanistically, absence of Irg1 potentiates lipid accumulation and lipid-mediated inflammation via a feed-forward cycle involving increased neutrophil extracellular trap (NET) formation, NET-induced NLRP3 inflammasome priming in macrophages, and subsequent IL-1b release. Conversely, supplementation of the Irg1 pathway using the derivative 4-octyl itaconate (4-OI) reduced atherosclerotic inflammation and promoted beneficial plaque remodeling in mice. To assess the therapeutic potential of 4-OI in humans, we leveraged a validated systems-immunology approach to investigate CVD-related inflammation ex vivo . Using high dimensional single cell analyses, we showed that 4-OI supplementation attenuated pro-inflammatory phospho-signaling in human peripheral blood mononuclear cells treated with plasma from CVD patients, and caused an anti-inflammatory rewiring of macrophage populations. Our data highlight the relevance of pursuing Irg1 -itaconate axis supplementation as a therapeutic approach to treat atherosclerosis in humans.
peripheral vascular disease,hematology